Paget's disease of bone: Indications for treatment and goals of therapy

被引:25
|
作者
Tiegs, RD [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA
关键词
Paget's disease of bone; osteoclasts; alkaline phosphatase; calcitonin; bisphosphonates;
D O I
10.1016/S0149-2918(97)80007-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Paget's disease of bone is a common disorder of unknown etiology characterized by increased bone remodeling and abnormal bone architecture. The pathologic process is initiated by an increase in osteoclast-mediated bone resorption, accompanied by a compensatory increase in bone formation. The increased bone remodeling results in a disorganized mosaic of woven and lamellar bone. This bone is highly vascular and gradually becomes enlarged and structurally weakened. Paget's disease is generally diagnosed in patients older than 40 years of age, usually as an incidental finding. The disease may be monostotic or polyostotic. The pelvis, femur, spine, tibia, skull, and humerus are most commonly involved. Most patients with Paget's disease are asymptomatic. Pain is the most common presenting symptom. Complications of the disease include bowing deformity of the long bones, fracture, and a variety of nerve compression syndromes. Malignant degeneration of Paget's disease is a rare complication. As safer, more effective therapies have become available, the indications for treatment and goals of therapy have changed. The difficult issue that clinicians are currently facing is whether to treat patients with asymptomatic disease. The progressive nature of the disease, the severity of its complications, its potential negative impact on quality of life, and the availability of therapy capable of controlling its activity have led many experts in the field to recommend treatment of asymptomatic patients who have active disease at sites where complications are likely to develop. There are, however, no data to prove that complications can be prevented by decreasing the rate of bone remodeling in Pager's disease, nor any data to define who is at risk for complications. Until more information is available, the management of patients with Paget's disease will continue to be based on clinical observation and theoretical considerations. This review examines the present understanding of Paget's disease, the rationale for the proposed indications for treatment, and the goals of therapy.
引用
收藏
页码:1309 / 1329
页数:21
相关论文
共 50 条
  • [1] Goals of treatment for Paget's disease of bone
    Siris, ES
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : 49 - 52
  • [2] Therapy of Paget's Disease of Bone
    Bernecker, P. M.
    JOURNAL FUR MINERALSTOFFWECHSEL, 2012, 19 (02): : 74 - 76
  • [3] Treatment of Paget's disease of bone
    Lojo Oliveira, Leticia
    Torrijos Eslava, Antonio
    REUMATOLOGIA CLINICA, 2012, 8 (04): : 220 - 224
  • [4] Treatment of Paget's Disease of Bone
    Urteaga, Elizabeth M.
    US PHARMACIST, 2012, 37 (10) : 29 - 34
  • [5] Treatment of Paget's disease of bone
    Arias M, Garcia
    Eslava A, Torrijos
    REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2011, 3 (01) : 35 - 40
  • [6] Medical management of Paget's disease of bone: Indications for treatment and review of current therapies
    Siris, Ethel S.
    Lyles, Kenneth W.
    Singer, Frederick R.
    Meunier, Pierce J.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : P94 - P98
  • [7] Alendronate in the treatment of Paget's disease of bone
    Khan, SA
    Vasikaran, S
    McCloskey, EV
    Beneton, MNC
    Rogers, S
    Coulton, L
    Orgee, J
    Coombes, G
    Kanis, JA
    BONE, 1997, 20 (03) : 263 - 271
  • [8] Diagnosis and treatment of Paget's disease of bone
    Schneider, D
    Hofmann, MT
    Peterson, JA
    AMERICAN FAMILY PHYSICIAN, 2002, 65 (10) : 2069 - 2072
  • [9] Treatment of patients with Paget's disease of bone
    Roux, C
    Dougados, M
    DRUGS, 1999, 58 (05) : 823 - 830
  • [10] Ibandronate treatment in Paget's disease of bone
    Grauer, A
    Heichel, S
    Knaus, J
    Dosch, E
    Ziegler, R
    BONE, 1999, 24 (05) : 87S - 89S